Silo Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on November 14, 2023, covering events occurring on November 10, 2023. The company is incorporated in Delaware and maintains its principal executive offices in Englewood Cliffs, New Jersey.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a material definitive agreement.
Material Changes
On November 10, 2023, Silo Pharma, Inc.'s wholly-owned subsidiary entered into a Third Amendment to a Master License Agreement with the University of Maryland, Baltimore. The primary change involves an amended and restated schedule of diligence milestones for the agreement.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard incorporation by reference of the agreement. The text notes that the description of the Third Amendment is not complete and refers readers to the full agreement attached as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the specific details of the amended diligence milestones in the Third Amendment (Exhibit 10.1).
- Confirm the impact of the revised milestones on the company's ability to maintain the license with the University of Maryland, Baltimore.
- Note that the company is not currently an emerging growth company based on the checkmarks in the filing.
- Review the full text of the Master License Agreement to understand the baseline obligations prior to this amendment.